Canada markets closed

Journey Medical Corporation (DERM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.6900+0.0600 (+1.65%)
At close: 04:00PM EDT
3.6200 -0.07 (-1.90%)
After hours: 04:04PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close3.6300
Open3.6300
Bid2.6300 x 200
Ask4.5500 x 200
Day's Range3.5200 - 3.7299
52 Week Range1.0200 - 8.1100
Volume51,779
Avg. Volume155,817
Market Cap73.55M
Beta (5Y Monthly)0.81
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer

    SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the appointment of Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024. Mr. Benesch had served as t

  • ACCESSWIRE

    Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV

    LAS VEGAS, NV / ACCESSWIRE / April 29, 2024 / Planet MicroCap presents the Planet MicroCap Showcase: VEGAS taking place on April 30 - May 2, 2024, where 96 MicroCap public and private companies will be presenting at the Paris Hotel & Casino in Las ...

  • GlobeNewswire

    Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024

    SCOTTSDALE, Ariz., April 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, announced today that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will present a corporate overview at the Pla